Bosutinib is a Src / Abl dual tyrosine kinase inhibitor approved for the treatment of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), or resistant or intolerant to previous trea...
The latest research found that some statins can improve the efficacy of chemotherapy drugs used to treat blood cancer in mouse models. Statins are drugs that treat patients with reduced fat in the blo...
Bone marrow fibrosis is a rare chronic disease of bone marrow hematopoietic cells. They benefit from JAK2 inhibitor drugs: symptom relief, prolonged survival, and improved quality of life. However, t...
On June 8 , the US FDA approved Venetoclax ( VENCLEXTA , AbbVie Inc. and Genentech Inc. ) for patients with chronic lymphocytic leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ), with or without ...
On June 12-13, FDA approved two new indications for K drug, just the day before the K drug was approved for the treatment of cervical cancer. One day later, the US FDA approved pembrolizumab (Keytrud...
In the United States, more than 70,000 people are diagnosed with non-Hodgkin's lymphoma each year, which is caused by excessive proliferation of immune cells in the body's lymph nodes. The most commo...
In recent years, the effect of immune checkpoint inhibitors on the treatment of Hodgkin's lymphoma (HL) is impressive, but the disease still needs to be overcome more thoroughly. Mayo Clinic ’s Lymp...
Researchers at the University of California, San Francisco and St. Jude Children ’s Research Hospital in Tennessee have solved medical mysteries decades ago, and they have discovered a pair of genet...
The FDA has granted its breakthrough drug quizartinib a breakthrough treatment. Quizartinib is a FLT3 inhibitor under investigation for the treatment of adult patients with relapsed / refr...
The US Food and Drug Administration approved Venetoclax (Venclexta) combined with rituximab (VenR) for the treatment of patients with chronic lymphocytic leukemia (CLL) based on the minimal residual d...